1. The study of rapamycin nanofibrous membrane for preventing arteriovenous fistula stenosis
- Author
-
Dan Rong, Taoxia Wang, Xiaoli Liu, Xiaolin Pan, Lijie Wang, Junfang Zhang, Peizhao Shi, Yaning Qin, Guiying Li, Lin Jin, and Zeyu Xiao
- Subjects
Chronic kidney disease ,Hemodialysis ,Arteriovenous fistula ,Arteriovenous fistula stenosis ,Rapamycin nanofibers ,Materials of engineering and construction. Mechanics of materials ,TA401-492 - Abstract
The maturity and patency of arteriovenous fistula (AVF) are essential for patients undergoing hemodialysis. Dysfunction of AVF due to neointimal hyperplasia (NIH) presents a significant clinical challenge. While balloon dilation therapy and open surgery can address this issue, they are associated with a higher likelihood of restenosis and reduced long-term durability. Therefore, there is an urgent need to establish a new method for inhibiting NIH to prolong the patency of AVF treatment. In this study, we developed a local vascular-encapsulated sustained-release drug delivery system containing degradable rapamycin nanofiber membrane patches (R-NFMs). During surgery, R-NFMs were wrapped around the anastomotic site of the AVF and the venous outflow tract. In vitro assessments demonstrated the consistent and stable release of rapamycin from the R-NFMs, confirming the material’s non-toxicity and its support of healthy cellular morphology. Animal studies further revealed that the experimental group showed significant reductions in neointimal and medial hyperplasia, as well as decreased expression of α-SMA, compared to controls. In conclusion, these findings suggest that R-NFMs are effective in inhibiting NIH and may serve as an innovative preventative approach to this pervasive issue.
- Published
- 2024
- Full Text
- View/download PDF